1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Novocure Ltd

Novocure Ltd

NVCR
Novocure LtdUS flagNASDAQ
15.57
USD
-0.43
- -
1.80BMarket Cap
Novocure Ltd
NVCR
(NASDAQ)

Recent

price

15.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.14
0.21
1.09
0.97
2
2.7
3.61
4.9
5.17
5.14
4.79
5.61
5.88
6
Revenue per Share
-1.07
-1.12
-3.67
-1.54
-0.7
-0.69
-0.07
0.2
-0.56
-0.88
-1.95
-1.56
-1.22
-1.54
Basic EPS, GAAP
-0.78
-1.06
-3.62
-1.46
-0.46
-0.09
0.17
0.83
0.57
0.09
-0.94
-0.64
-0.68
-0.43
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.71
-3.83
-12.77
-6.08
-6.58
-7.01
-6.69
-6.25
-6.63
-7.44
-9.26
-10.7
-11.58
-12.11
Book Value per Share
2.38
1.36
8.25
1.66
1.28
1.22
2.24
4.72
3.97
4.22
3.41
3.34
3.05
2.94
Tangible Book Value per Share
72
72
30
86
89
92
97
101
103
105
106
108
111
112
Basic Weighted Avg Shares
10
15
33
83
177
248
351
494
535
538
509
605
655
674
Sales/Revenue/Turnover
-622.25
-517.47
-314.31
-139.12
-22.22
-13.57
-0.26
6.15
-8.29
-16.64
-45.72
-28.17
-23.47
-27.19
Operating Margin (%)
1
2
3
6
8
9
8
9
10
11
11
11
15
15
Depreciation Expense
-77
-81
-112
-132
-62
-64
-7
20
-58
-93
-207
-169
-136
-173
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-746.89
-520.87
-337.24
-159.06
-34.83
-25.62
-2.06
4.01
-10.91
-17.2
-40.65
-27.86
-20.79
-25.66
Profit Margin (%)
168
94
265
225
195
257
354
886
931
953
855
350
424
414
Working Capital
- -
- -
23
97
98
149
164
444
575
584
596
117
237
235
LT Debt
172
98
251
142
114
112
218
477
410
441
362
360
340
331
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
561
12
- -
LT Borrowings
195
195
195
LT Finance Leases
43
42
39
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
116
Market Capitalization
1,428
1,442
1,226

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,200
647
632
Cash, Cash Equivalents & STI
1,034
448
432
Accounts Receivable, Net
85
89
93
Inventories
39
41
43
Total Current Liabilities
776
223
218
Payables & Accruals
215
196
218
ST Debt
561
12
- -
Deferred Revenue
- -
16
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.79%
-6.07%
-5.47%
Free Cash Flow
-130.02%
-260.21%
9.32%
Net Income, GAAP
-74.46%
-50%
-19.21%
Sales/Revenue/Turnover
41.71%
6.11%
8.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
150
155
161
605
2025
155
159
167
174
655
2026
174
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.31
-0.28
-0.61
-1.56
2025
-0.31
-0.36
-0.33
-0.22
-1.22
2026
-0.62
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Beijing Chunlizhengda Medical Instruments Co., Ltd. (1858.HK)
Xylo Technologies Ltd. (XYLO)
Lucira Health, Inc. (LHDX)
MagForce AG (MGFRF)
Vascular Solutions LLC (VASC)
Southern Home Medical, Inc. (SHOM)
Business
NovoCure Limited (Nasdaq: NVCR) is a global oncology company that develops, manufactures and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive anti-mitotic treatment delivered via wearable devices that disrupt cancer cell division in solid tumors. Its main commercialized products include Optune Gio, approved for adult patients with glioblastoma (GBM), and Optune Lua, approved for malignant pleural mesothelioma (MPM); in 2024, the U.S. FDA expanded approvals to include TTFields therapy concurrently with PD-1/PD-L1 inhibitors or docetaxel for metastatic non-small cell lung cancer (mNSCLC) following platinum-based therapy, and approved new Head Flexible Electrode (HFE) transducer arrays to enhance patient comfort in GBM treatment. The company conducts Phase 3 clinical trials such as PANOVA-3 (pancreatic cancer), LUNAR-2 and METIS (lung and brain metastases), and TRIDENT (ovarian cancer), targeting additional aggressive cancers. Founded in 2000 and headquartered in Baar, Switzerland, with U.S. operations in Portsmouth, New Hampshire, and R&D in Haifa, Israel, NovoCure operates in the United States, Germany, France, Japan, Greater China and other international markets. Recent developments include the January 2025 inauguration of new global headquarters in the Canton of Zug, Switzerland, to support expansion; a multi-tranche $400 million non-dilutive debt financing with Pharmakon Advisors, with $100 million drawn at closing and more available through 2025; and positive topline results from the Phase 3 PANOVA-3 trial demonstrating statistically significant overall survival improvement in unresectable pancreatic cancer.

Company News

APIChatGPT

  • zacks.com

    NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • seekingalpha.com

    NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • zacks.com

    NovoCure's Cancer Treatment Device Option Pax Gets European Approval

  • businesswire.com

    Novocure to Report Second Quarter 2026 Financial Results

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • businesswire.com

    Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

  • fool.com

    HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

  • fool.com

    NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

  • gurufocus.com

    NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

  • businesswire.com

    NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

  • fool.com

    Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

  • prnewswire.com

    Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

  • reuters.com

    Novocure's cancer treatment fails to meet late-stage trial goal

  • businesswire.com

    Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

  • fool.com

    CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing